Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022 Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program ...